Ethypharm, Inc.

Ethypharm Sa

Catherine Herry

Pascal Oury

Pauline Contamin

Frantz Deschamps

Caroline Ailhas

Yann Prevost

Vincent Billoet

Johnatan Bacon

Fabrice Leboeuf

Jennifer Jung

Gaël Lamoureux

Guillaume Benoist

Didier Hoarau

Maryline Boyer

Jonathan Bacon

Vincent Cailly-Dufestel

Joseph Duvochel

Laury Trichard-Trolet

Laury Trichard

Francoise Vauzelle-Kervroedan

Emmanuel Dupau

Françoise Vauzelle-Kervroedan

The present invention relates to granules of active ingredient with double taste masking, wherein the double taste masking is achieved by a hot-melt compound selected from waxes, hydrogenated vegetable oils, fatty acids, mono-, di- and triesters of fatty acids and of glycerol, triglycerides, glycerides, polyoxylglycerides, fatty alcohols, and mixtures thereof, and a thermoplastic polymer that is soluble at a pH less than or equal to 5. The invention also relates to the method for producing these granules and to orodispersible tablets containing these coated granules.

Granules of an active substance with double taste-masking technique, method for the production thereof, and orodispersible tablets containing same

The invention relates to an oral pharmaceutical composition in the form of a sustained-release tablet comprising an active ingredient capable of being misused, which composition makes it possible to combat misuse by injection.

Tablet capable of combatting misuse by injection

The present invention concerns an oral pharmaceutical formulation made from a microemulsion between an aqueous solution comprising at least one BCS (Biopharmaceutics Classification System) class III active principle and one oily phase comprising an oily vehicle that is self-emulsifiable on contact with water.

Oral pharmaceutical formulation of BCS class III molecules

The present invention relates to the use of a sustained release matrix containing at least one opioid for producing a solid oral formulation in table form suitable for reducing blood concentration fluctuations of said opioid.

Reduction of opioid blood fluctuations

A sustained release oral pharmaceutical form suitable for single daily dose administration has a neutral microgranule coated with a mounting layer of active ingredient and pharmaceutically acceptable binder; and a coating layer of a hydrophobic coating polymer of a non-water soluble cellulose derivative, and at least 20% of inert load in relation to dry weight of hydrophobic coating polymer. The pharmaceutical form has improved resistance to rapid release of active ingredient, particularly in the presence of alcohol.

Alcohol-resistant oral pharmaceutical form

The present invention relates to an oral and/or buccal composition in the form of a thin film of a pharmaceutically active ingredient weakly soluble in water and gastro-intestinal tract fluids, comprising particles of said active ingredient dispersed in a film-forming polymer, at least 50% by weight of the total weight of the active ingredient having a particle size distribution such that at least 90% of said particles have a size below 1000 nm, preferably less than 800 nm, and even more preferably less than 600 nm, and to the method of preparing that composition and the use thereof.

Oral and/or buccal composition in the form of a thin film of a weakly soluble active ingredient, method of preparing same and use of same

Oral pharmaceutical form containing microgranules for the sustained release of at least one active principle, including a neutral carrier that is insoluble in water or in an alcohol solution, or a neutral carrier rendered insoluble in water or an alcohol solution, comprising at least one first mounting layer containing at least one active principle and optionally a pharmaceutically acceptable binding agent, wherein the whole comprises at least one coating based on at least one hydrophobic polymer.

Alcohol-resistant sustained-release oral pharmaceutical form based on microgranules

The present invention relates to a fentanyl coated tablet and to the method for the preparation thereof.

Sublingual coated tablet of fentanyl

An orally disintegrating multilayer tablet comprising at least two discrete layers, one of which comprises at least one active agent that promotes the oxidation of opioids, preferably acetaminophen, and the other of which contains granules including an inert core which is coated with at least one opioid and at least one binder, wherein said opioid coating is coated with a subcoat comprising a compound soluble in gastric fluids, said subcoat being coated with a taste-masking coating comprising a polymer or copolymer comprising dialkylaminoalkyl(meth)acrylate units and a pore-forming agent.

Multilayer orally disintegrating tablet

Water-insoluble matrix tablets based on oxycodone or one of its pharmaceutically acceptable salts and capable of prolonged release of oxycodone to the body, exhibiting a crush resistance of at least 4 MPa.

Crush-resistant oxycodone tablets intended for preventing accidental misuse and unlawful diversion

The present invention relates to a multilayer orodispersible tablet and to the process for preparing it.

Growing community of inventors

Saint-Ouen du Tilleul, France

Catherine Herry